Company intelligence / Profile preview

Kamedis

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Kamedis has developed a line of dermatologist-tested, clinically proven botanical skincare products. A double-blind randomized clinical study showed their Calm Eczema Therapy Cream was significantly more effective than both non-botanical formulations and leading OTC competitors for atopic dermatitis. No adverse events were reported. Products are sold worldwide and have received CE mark approval in Europe.

Therapeutic areas: Dermatology
Modalities: Botanical extract therapy (proprietary combinations of traditional Chinese medicinal herbs)Non-pharmacological therapy (over-the-counter topical products)Small molecule (plant-derived actives)
Industry: Therapeutic Medical Devices

Partnerships

Seeking strategic partnerships in China with large dermo-cosmetic players; no major pharma partnerships disclosed as of latest reports.

Beyond the preview

Go deeper on Kamedis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kamedis.

Explore the full profile